Parisinos CA, et al. - Researchers used the effect of rs2228145 on soluble IL6R (s-IL6R) level as an indirect marker to examine whether reduced IL6R signaling associated with risk of ulcerative colitis (UC) or Crohn’s disease (CD). In a genome-wide meta-analysis of twenty thousand, five hundred fifty patients with CD, 17647 patients with UC, and more than 40,000 individuals without inflammatory bowel diseases (IBD) (controls), they found that rs2228145 was linked with reduced risk of CD or UC. Results of this study suggested that therapeutics designed to block IL6R signaling could be effective in the treatment of IBD.